All lobbying filings

TODD STRATEGY GROUP

TODD STRATEGY GROUP filed a Q3 report for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA on October 19, 2026, reporting $80,000 in lobbying income.

Lobbying for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · Trade association representing biopharmaceutical research companies.

All filings by TODD STRATEGY GROUP · Everything PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA has reported

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 19, 2026

Income

$80,000

What the client paid this registrant for the period.

Client based in

District of Columbia

Official filing document

Lobbyists on this filing 5

PAUL EDATTEL

Previously held: Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg
DANIEL M TODD

Previously held: Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid
ERIC BERGREN

Previously held: Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker
KATHERINE FLEMING COTTON

Previously held: Staff Assistant, Legislative Correspondent, Legislative Assistant - U.S. Representative Brett Guthrie
NICOLAS MAGALLANES

Previously held: Senior Advisor - House Republican Conference; Policy Advisor/Professional Staff Member - U.S. Representative Lee Terry/Energy and Commerce Committee; Legislative Correspondent/Legislative Aide - U.S. Senator Lamar Alexander

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 6

Budget/Appropriations

Presidents Budget Fiscal Year 2027. Government funding policy issues.

Biopharmaceutical innovation policy issues. Biosimilar approval and reimbursement policy issues.

Pharmacy

User fee issues. Vaccine policy issues. Pharmacy Benefit Manager reform and policy issues. Drug cost and pricing policy issues. Most Favored Nation (MFN) policy issues. Drug importation policy issues. FDA policy issues. Competition policy issues. Orphan Drug Act policy issues. Antimicrobial resistance policy issues. Supply chain policy issues. 340B drug discount program rebate and policy issues. Drug shortages policy issues . Executive Order 14297: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients. Executive Order 14273: Lowering Drug Prices by Once Again Putting Americans First. Biopharmaceutical innovation policy issues. Pricing and reimbursement policy issues. Inflation Reduction Act of 2022 (Public Law 117-169) implementation policy issues.

Health Issues

Patient assistance program policy issues.

Medicare/Medicaid

H.R.1: One Big Beautiful Bill Act (Public Law 119-21). Part D redesign and policy issues including non-interference and rebates policy issues. Part B policy issues. Drug cost and pricing policy issues. Medicare rebate policy issues. Center for Medicare and Medicaid Innovation (CMMI) policy issues. CMS IPAY Guidance on the Medicare Drug Price Negotiation Program. IPAY and Maximum Fair Prices policy issues. Medicaid rebate policy issues. GENErating cost Reductions for U.S. Medicaid (GENEROUS) model. Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule. Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule. IRA price negotiation expansion policy issues.

Trade (domestic/foreign)

Tariff policy issues.

Bills named in this filing 1

H.R. 1
One Big Beautiful Bill Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.